Creative Bioarray offers a broad range of well-characterized xenograft, patient-derived xenograft (PDX), syngeneic tumor models as well as genetically engineered mouse models (GEMMs). Combining these models with appropriate biomarkers, including flow cytometry and imaging, our portfolio allows our partners to select the most appropriate study design and screening method to identify promising compounds and optimize lead candidates.

https://dda.creative-bioar...

Only people mentioned by creativebioarray in this post can reply

No replys yet!

It seems that this publication does not yet have any comments. In order to respond to this publication from Hannah Cole, click on at the bottom under it